SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Daniel Acker — Bloomberg via Getty Images

78

Merck

MRK

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.

Looking for leads, investment insights, or competitive intelligence?

CEO

Kenneth C. Frazier

CEO Title

Chairman, President & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, N.J.

Years on Fortune 500 List

24

Employees

69,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$40,1220.8%
Profits ($M)$2,394.0-38.9%
Assets ($M)$87,872
Total Stockholder Equity ($M)$34,336
Market Value — as of March 29, 2018 ($M)$146,862
Profit Ratios
Profit as % of Revenues6.0%
Profits as % of Assets2.7%
Profits as % of Stockholder Equity7.0%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)0.87
EPS % Change (from 2016)-38.3%
EPS % Change (5 year annual rate)-15.3%
EPS % Change (10 year annual rate)-5.2%
Total Return
Total Return to Investors (2017)-1.5%
Total Return to Investors (5 year, annualized)10.1%
Total Return to Investors (10 year, annualized)3.5%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

4 Rules Every Activist CEO Should Follow

CEOs' decisions have the power to change society—not just stock prices.

Read More →
Eli Lilly, AstraZeneca's Alzheimer's Drug Flop Is the Latest Disappointment in a Frustrating Disease

The story of Alzheimer's drug development is one of perpetual tragedy and setbacks.

Read More →
The CEO Action for Diversity and Inclusion Turns Two

The alliance of nearly 500 chief executives reports a successful first year in addressing inclusion at their firms and has big goals ahead.

Read More →